NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2008 November 15.

Published in final edited form as:
Bioorg Med Chem Lett. 2007 November 15; 17(22): 6206–6211.

Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of $GABA_B$ receptors

Sébastien Guery[a], **Philipp Floersheim**, **Klemens Kaupmann**[b], and **Wolfgang Froestl**[c]
Novartis Institutes for Biomedical Research, Neuroscience, Novartis Pharma A.G., CH-4002 Basel, Switzerland.

Abstract

The optimization of GS39783 into potent, selective and safe positive allosteric modulators of $GABA_B$ receptors is presented.

The receptors for the major inhibitory neurotransmitter in the central nervous system, GABA, are subdivided into ionotropic $GABA_A$and $GABA_C$ receptors and metabotropic $GABA_B$ receptors. Whereas $GABA_A$ and $GABA_C$ receptors form chloride-permeable ion channels, $GABA_B$ receptors are G-protein coupled receptors (GPCRs). These receptors were discovered in 1980 by Norman G. Bowery [1]and act post and pre-synaptically to inhibit neuronal excitability and neurotransmitter release, respectively. A possible role of $GABA_B$ receptors in a large number of CNS disorders such as cognition deficits, anxiety, depression, epilepsy, pain and drug addiction has been discussed.[2] Some of these diseases like anxiety, pain and drug addiction could potentially be treated by activation of $GABA_B$ receptors, which can be achieved by administration of either agonists or positive allosteric modulators. Whereas benzodiazepines are well known positive allosteric modulators of $GABA_A$ receptors, the first examples of allosteric enhancers for $GABA_B$ receptors have been described only recently.[3] One of the most interesting compound found was GS39783 (Figure 1).[3b] However, despite an interesting *in vitro* and *in vivo* profile, [3b,4] GS39783 was found to be genotoxic probably because of its aromatic nitro group (Figure 1)[5]5.

This communication describes our efforts towards the identification of a novel, drug-like class of compounds acting as positive allosteric modulators for $GABA_B$ receptors.

In order to introduce molecular diversity in position 5 of the pyrimidine ring, a 4 steps procedure depicted in Scheme 1 was optimized in order to obtain compounds with a chlorine or with a hydrogen in position 6. 4,6-dichloro-2-methylpyrimidine was first substituted by cyclopentylamine and then iodinated to lead to compound **6**. This scaffold was then used in a Suzuki cross coupling[6] to give very efficiently a small focused library of substituted 4-amino-6-chloro-5-phenylpyrimidines (Cpds **7a–15a**) which were then hydrogenated under standard conditions to give the desired 4-amino-5-phenylpyrimidines (Cpds **7b–15b**). As a

Correspondence to: Sébastien Guery; Klemens Kaupmann; Wolfgang Froestl.
[a]Sébastien Guery, GlaxoSmithKline S.p.A., Via A. Fleming 4, 37135 Verona, Italy, tel : 00 39 045 821 9042, fax : 00 39 045 821 8196, e-mail: sebastien.2.guery@gsk.com
[b]Klemens Kaupmann, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland, tel: 00 41 61 696 34 73, e-mail: klemens.kaupmann@novartis.com
[c]Wolfgang Froestl, AC Immune SA, PSE Building B, EPFL, CH-1015 Lausanne, Switzerland, tel : 00 41 21 693 91 26, fax : 00 41 21 693 91 20, e-mail: wolfgang.froestl@acimmune.com

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

means to introduce molecular diversity at the last step in position 4 of the pyrimidine ring, a versatile way of synthesis was designed (Scheme 2). Starting from the commercially available 5-bromo-2,4-dichloropyrimidine, a regioselective nucleophilic substitution was performed in position 4 exclusively to give the 4-methylthio derivative **17**[7] which was then involved in a halogen exchange[8] to give 2-iododerivative **18**. The 2-methyl group and the 5-[(4-trifluoromethyl)phenyl] substituents were introduced by a Negishi cross coupling[9] and a Suzuki cross coupling,[10] respectively to afford **20**. Our first attempt was to oxidize the methylsulfide moiety of **20** to the corresponding methylsulfonyl (**21**) by treatment with mCPBA[11] and then to use **21** as a template. Unfortunately, only few amines reacted cleanly with **21** probably because of the steric hindrance near the leaving group. Our second attempt was to hydrolyze the methylsulfide moiety of **20** with hydrochloric acid[12] to give **23** (Scheme 3). This compound was then reacted with $POCl_3$ to give the corresponding 4-chloropyrimidine **24**. This useful intermediate was submitted to nucleophilic substitutions with a collection of amines to give compounds **25–34**. Finally the third library with molecular diversity in position 2 was synthesized starting from compound **16**, which was substituted first with exo-2-aminonorbornane[13] and then with MeSNa to give **36** (Scheme 4). The phenyl moiety was introduced by a Suzuki cross coupling to afford **37**37. On one hand, a desulfurization by treatment with Ni-Raney in EtOH[14] leads to **39** and on the other hand **37** can also be oxidized into the corresponding 2-methylsulfonylpyrimidine **38** which was then reacted with various nucleophiles.

Thanks to a preliminary work with nitro-mimetics (Figure 2), we found that to replace the nitro group, we should have a lipophilic substituent (see Cpd **3**) with an electron-withdrawing effect (see Cpds **1** and **2**). One way to combine both of these effects is to substitute the position 5 of the pyrimidine ring by a substituted phenyl. Moreover, substantial efficacy in the biological assay[15] was observed for compounds with only one cyclopentylamine substituent in position 4 of the pyrimidine ring (compare **1** with **2** and **3** with **4**). Furthermore, it was also shown earlier that the replacement of the 2-methylthio substituent by a 2-methyl group is not detrimental for the activity.[3b] After screening for $GABA_B$ receptor positive modulatory activity of the first library of compounds (Table 1), we found that the 6-chloro substituent was detrimental to the efficacy at the receptor (compare for example **8a** with **8b** at 25 μM of compound, **12a** with **12b** and **15a**) with **15b**. Moreover, the introduction of a second cyclopentylamino substituent in position 6 led to only weakly active or inactive compounds (data not shown) confirming our hypothesis that the space in the receptor is very limited and that a proton is the best substituent for the position 6 of the pyrimidine ring. On the other hand, as postulated before, electron-withdrawing groups on the phenyl ring such as a 4-trifluoromethyl or a 4-trifluoromethoxy showed the best results (compare **9b** with **12b** and **10b** with **15b**). Indeed, the replacement of a 4-methylphenyl (**9b**) or 4-methoxyphenyl (**10b**) by a 4-trifluoromethylphenyl (**12b**) or a 4-trifluoromethoxyphenyl (**15b**) led to more efficacious positive modulators (Table 1). Other electron-withdrawing substituents were used on the phenyl ring but none of them had increased activity at the receptor compared to the trifluoromethyl or trifluoromethoxy groups (data not shown). The introduction of a substituent in position 3 of the phenyl ring led to a decrease of activity (compare **14b** with **15b**). To conclude, the best nitro-mimetic group identified in this series was a 4-(trifluoromethyl)phenyl substituent. Then we focused our attention on position 4 of the pyrimidine ring (Scheme 2 and Scheme 3).

This collection of compounds shows interesting structure activity relationships (Table 2). For this series it became obvious that an increased size of the cycloalkyl led to increased efficacy. This trend was first observed with compound **29** in which the cyclopentyl substituent was replaced by a cycloheptyl (compare **12b**b and **22** with **29** at 2.5 μM). Interestingly, the introduction of an additional bulky substituent on the cyclohexyl ring (**30**) led to a less active product (compare **30** with **22**). Moreover, the introduction of an aromatic ring onto the amino group was not tolerated by the receptor (compare **31**, **32**, **34** with **22**) therefore we thought that

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

a hydrophobic interaction with a spatially extended substituent was necessary at this position. Surprisingly, despite its 4-tert-butylamino substituent, **33** was found to be a weak positive modulator. The needs of bulky, cyclic aliphatic side chain was then confirmed when cycloalkyl chains were used such as a norbornyl (**27**), an adamantyl (**25**),(**26**) or a cycloheptyl (**29**). A substantial increase in activity was observed when comparing **29** to **12b** and to **22**. Despite its good efficacy, **29** was not investigated any further because of significant binding activities to other GPCRs (data not shown). We were then interested in compounds **25** and **26** bearing an adamantyl substituent on the amino group. Both compounds showed were potent positive allosteric modulators (Table 2) which led to the hypothesis that the substituents in position 4 of the pyrimidine ring bind into a large lipophilic pocket in the receptor. However, again these products were not considered for further evaluation despite an increased selectivity profile because of their high logPs (log P > 5.9) and low water solubilities (< 10 $mg.L^{-1}$). Finally, we focused our attention on **27** which bears a norbornyl group at its amino function. Both the *exo* isomer (**27**) and the *endo* isomer (**28**) were evaluated (Table 2). Compound **27** was more efficacious, and was of similar potency and efficacy compared to GS39783. Genotoxicity[16] and mutagenicity[17] assays were performed and **27** was found to be safe both in the micronucleus test and in the Ames test. For that reason **27** was considered for further *in vitro* and *in vivo* evaluations and the exo-2-norbornyl substituent was kept for the optimization of the position 2.

Finally the screening of the collection of compounds with molecular diversity in position 2 gave surprising results (Table 3). The replacement of the methyl moiety of **27** by an hydrogen led to a less active compound which indicated that a substitution at this position is mandatory. The introduction of a 2-SMe group (**37**), a methylsulfonyl (**38**) or a methylamino (**42**) were detrimental for activity (compare **37**, **38** and **42**42 with **27**). In contrast, the replacement of a 2-methyl group by a cyano (**40**), a methoxy (**41**) or a dimethylamino (**43**) gave compounds with a similar potency than GS39783. Surprisingly, the introduction of a N-methylpiperazin-1-yl (**44**) reduced the biological activity suggesting that the space in the receptor is limited and that only small substituents are tolerated. Compounds **40**, **41** and **43** are currently under evaluation for their physicochemical and pharmacokinetics properties as well as their full pharmacological characterization.

Positive allosteric modulators of $GABA_B$ receptors represent an interesting class of therapeutic agents for the treatment of anxiety and drug addiction. Despite its good *in vitro* and *in vivo* potency, GS39783 was only useful as a pharmacological tool because of its genotoxicity. We report herein a new class of positive allosteric modulators of $GABA_B$ receptors derived from GS39783 with an increased drug-likeness, a decreased toxicity and an excellent selectivity profile. Some *in vivo* investigations are currently on going in anxiety and drug addiction models and the results of these studies will be reported in due course.

Acknowledgments

This work was supported by National Institutes of Mental Health/National Institute on Drug Abuse Grant U01 MH69062.

References and Notes

1. Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J, Turnbull M. Nature 1980;283:92. [PubMed: 6243177]
2. (a) Marshall FH. J. Mol. Neurosci 2005;26(2–3):169. [PubMed: 16012190] (b) Cryan JF, Kaupmann K. Trends Pharmacol. Sci 2005;26(1):36. [PubMed: 15629203] (c) Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Physiol. Rev 2004;84:835. [PubMed: 15269338]
3. (a) Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, Bettler B, Kaupmann K. Mol. Pharmacol 2001;60:963. [PubMed: 11641424] (b) Urwyler S, Pozza MF, Lingenhoehl K,

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Mosbacher J, Lampert C, Froestl W, Koller M, Kaupmann K. J. Pharmacol. Exp. Ther 2003;307(1): 322. [PubMed: 12954816]

4. Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoel K, Froestl W, Bettler B, Kaupmann K, Spooren WPJM. J. Pharmacol. Exp. Ther 2004;310(3):952. [PubMed: 15113848]
5. (a) Purohit V, Basu AK. Chem. Res. Toxicol 2000;13:673. [PubMed: 10956054] (b) Tocher JH. Gen. Pharmacol 1997;28:485. [PubMed: 9147012]
6. Richardson ML, Stevens MFG. J. Chem. Res., Synop 2002:482.
7. Strekowski L. Bull. Pol. Acad. Sci., Chem 1976;24(1):17.
8. Vlad G, Horvath IT. J. Org. Chem 2002;67:6550. [PubMed: 12201781]
9. Hocek M, Votruba I, Dvorakova H. Tetrahedron 2003;59:607.
10. Hannah DR, Sherer EC, Davies RC, Titman RB, Laughton CA, Stevens MFG. Bioorg. Med. Chem 2000;8:739. [PubMed: 10819163]
11. Herrera A, Martinez-Alvarez R, Chioua R, Benabdelouahab F, Chioua M. Tetrahedron 2004;60:5475.
12. Strekowski L, Harden D, Watson RA. Synthesis 1988;70
13. Brumby, T.; Jautelat, R.; Prien, O.; Schaefer, M.; Siemeister, G.; Luecking, U.; Huwe, C. WO. 2002096888. 2002.
14. Morimoto H, Shimadzu H, Kushiyama E, Kawanishi H, Hosaka T, Kawase Y, Yasuda K, Kikkawa K, Yamauchi-Kohno R, Yamada K. J. Med. Chem 2001;44:3355. [PubMed: 11585441]
15. GTP(γ)^{35}S binding was used as functional assay for $GABA_B$ receptor activity (see reference 3b). To assay for positive modulatory activity the compounds were co-applied with GABA. 1μM GABA stimulates $GABA_B$ receptors to approximately EC_{20} values, 20μM GABA stimulates to approximately EC_{80} values. If co-application of the test compounds with GABA significantly increased the signal above EC_{20} (at 1μM GABA) or EC_{80} (at 20μM GABA) we concluded that the compound positively modulated the GABA response. In control experiments the test compounds were assayed in the absence of GABA. For selected compounds, concentration-response curves were generated and the EC_{50} values and maximal stimulations at a GABA concentration of 1μM determined.
16. (a) Fenech M. Mutat. Res 2000;455(1–2):81. [PubMed: 11113469] (b) Miller B, Albertini S, Locher F, Thybaud V, Lorge E. Mutat. Res 1997;392(1–2):45. [PubMed: 9269330]
17. Flamand N, Meunier J-R, Meunier P-A, Agapakis-Caussé C. Toxicology in vitro 2001;15:105. [PubMed: 11287170]

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript



Figure 1.
Structure of GS39783



Figure 2.

Biological activity of some GS39783 derivatives bearing nitro-mimetics in position 5. The potentiation of the GABA-induced stimulation of GTP(γ)^{35}S binding was measured using membranes from $GABAB_{B(1b/2)}$ expressing CHO-K1 cells as described. [3a] The activities of compounds (25 µM) were determined in the presence of 20 µM GABA. The data are normalized to the maximal effect (100%) obtained with a saturating concentration of GABA (1mM). 20 µM GABA, when applied alone, stimulates to approximately EC_{80} levels (80%).

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript



Scheme 1.

Reagents and conditions: (a): cyclopentylamine (4.0 eq.), dioxane, 0°C to RT, 24h; (b): NIS, DMF, 80°C, 24h ; (c): arylboronic acid (1.05 eq.), $Pd(OAc)_2$ (0.02 eq.), dppf (0.03 eq.), K_3PO_4 (2.0 eq.), DME, water, 85°C ; (d): Pd/C 10%, AcONa (1.1 eq.), EtOH, H_2, RT.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript



Scheme 2.

Reagents and conditions: (a): MeSNa, THF, RT; (b): HI 57%, RT; (c): MeZnCl, $Pd(PPh_3)_4$, THF, RT to 60°C; (d): 4-trifluoromethylbenzeneboronic acid, Na_2CO_3, $Pd(PPh_3)_4$, EtOH, Toluene, water, 110°C; (e): mCPBA, DCM, RT; (f): cyclohexylamine, DMF, 150°C, microwaves, 20 min.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript



Scheme 3.

Reagents and conditions: (a): HCl 37%, MeOH, reflux; (b): $POCl_3$3, one drop of DMF, 80°C; (c): R-NH_2, solvent, Base, 80°C.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript



Scheme 4.

Reagents and conditions: (a): exo-2-aminonorbornane, THF, 0°C to RT; (b): MeSNa, THF, 0° C to RT; (c): 4-trifluoromethylbenzeneboronic acid, Na_2CO_3, $Pd(PPh3)_4$, toluene, EtOH, water, 110°C; (d): Ni-Raney, EtOH, 60°C; (e): mCPBA, DCM, RT, 1.5h; (f): Cpd **40**: KCN, DMSO, 80°C. Cpd **41**: Sodium methoxide, THF, RT. Cpd **42**: methylamine, EtOH, RT. Cpd **43**: dimethylamine, THF, 80°C. Cpd **44**: N-methylpiperazine, THF, 80°C.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Table 1

Biological activities obtained for compounds **7a–15b**. The compounds were assayed as described.[3,15] When applied alone, 1μM GABA stimulates to approximately EC_{20} levels (20% stimulation). The effects (%) are normalized to the maximal effect of a saturating concentration of GABA (1mM). Values were calculated from triplicate measurements. pEC_{50} and E_{max} values were calculated from concentration-response curves (8 concentrations) in the presence of 1μM of GABA.

Cpd	R	2.5 μM of Cpd, 1 μM of GABA Effect (%) ± sem	25 μM of Cpd, 1 μM of GABA Effect (%) ± sem	1 μM of GABA	
				pEC_{50} ± sem	E_{max}(%) ± sem
GS39783	-	132 ± 4	153 ± 2	6.13 ± 0.06	146 ± 5
7a	4-*n*Butyl	27 ± 1	39 ± 1	-	-
7b		25 ± 1	18 ± 3	-	-
8a	4-Ethyl	23 ± 2	39 ± 2	-	-
8b		29 ± 1	61 ± 1	-	-
9a	4-Ethyl	23 ± 2	34 ± 1	-	-
9b		23 ± 2	41 ± 2	-	-
10a	4-Methoxy	21 ± 1	29 ± 1	-	-
10b		21 ± 1	38 ± 2	-	-
11a	3-Methyl	25 ± 1	36 ± 1	-	-
11b		21 ± 0	28 ± 2	-	-
12a	4-CF_3	17 ± 1	26 ± 1	-	-
12b		62 ± 3	114 ± 2	5.30 ± 0.03	127 ± 3
13a	4-COOEt	14 ± 1	5 ± 3	-	-
13b		26 ± 0	31 ± 0	-	-
14a	3-OCF_3	20 ± 1	33 ± 1	-	-
14b		23 ± 1	25 ± 1	-	-
15a	4-OCF_3	19 ± 1	35 ± 1	-	-
15b		48 ± 3	100 ± 3	5.34 ± 0.07	117 ± 7

Bioorg Med Chem Lett. Author manuscript; available in PMC 2008 November 15.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Table 2

Biological activities obtained for compounds **22, 25–34**. The compounds were assayed as described under Table 1. Compounds **25–27**, **29** and **34** have a relatively low water solubility due to their high lipophilicity. This is reflected in this assay by a similar or reduced activity at 25 μM versus 2.5 μM. Concentration-dependent increase in activity however was observed in full concentration response curves, with maximal effects at 10 μM.

Cpd	R	2.5 μM of Cpd, 1 μM of GABA Effect (%) ± sem	25 μM of Cpd, 1 μM of GABA Effect (%) ± sem	1 μM of GABA	
				pEC_{50} ± sem	E_{max} (%) ± sem
22		80 ±1	93 ± 5	6.06 ± 0.05	83 ± 4
25		90 ± 1	80 ± 2	5.56 ± 0.13	132 ± 14
26		125 ± 4	141 ± 6	5.46 ± 0.10	185 ± 15
27		122 ± 3	110 ± 0	5.78 ± .03	183 ± 4
28		82 ± 5	52 ± 4	-	-
29		128 ± 4	70 ± 4	5.78 ± 0.03	137 ± 3
30		28 ± 1	32 ± 2	-	-
31		36 ± 2	69 ± 6	-	-
32		29 ± 1	39 ± 2	-	-

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Cpd	R	2.5 μM of Cpd, 1 μM of GABA Effect (%) ± sem	25 μM of Cpd, 1 μM of GABA Effect (%) ± sem	1 μM of GABA	
				pEC_{50} ± sem	E_{max} (%) ± sem
33		40 ± 3	21 ± 7	-	-
34		58 ± 11	59 ± 4	-	-

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Table 3

Biological activities obtained for compounds **37-44**. The compounds were assayed as described under Table 1.

Cpd	R	2.5 μM of Cpd, 1 μM of GABA Effect (%) ± sem	25 μM of Cpd, 1 μM of GABA Effect (%) ± sem	1 μM of GABA	
				pEC_{50} (μM) ± sem	E_{max}(%) ± sem
37	-SMe	82 ± 7	91 ± 4	-	-
38	Me-SO_2-	24 ± 7	30 ± 12	-	-
39	H	48 ± 3	63 ± 4	-	-
40	-CN	117 ± 3	127 ± 1	5.92 ± 0.11	198 ± 21
41	-OMe	115 ± 2	131 ± 6	5.69 ± 0.13	191 ± 21
42	-NHMe	20 ± 3	25 ± 8	-	-
43	-NMe_2	94 ± 4	126 ± 7	5.78 ± 0.08	167 ± 16
44	N-methylpiperazine	26 ± 8	112 ± 7	-	-